Vancocin® HCl (Vancomycin Hydrochloride for Injection USP) is a lyophilized powder, for preparing intravenous (IV) infusions, in vials each containing the equivalent of 500 mg or 1 g vancomycin base. Vancocin® HCl (Vancomycin Hydrochloride for Injection USP) is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactamresistant) staphylococci
Month: November 2022
Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. As an antibody with reduced fucose content, obinutuzumab induces greater ADCC activity than rituximab in vitro using human cancer cell lines. Obinutuzumab also demonstrated an increased ability to induce direct cell death when compared to rituximab.
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.
Lacillin is indicated in the treatment of gastrointestinal, respiratory, systemic and urogenital infections caused by or associated with pathogens sensitive to ampicillin therapy. These infections include biliary-tract infections, bronchitis, endocarditis, epiglottitis, gonorrhea, listeriosis, meningitis, otitis media, peritonitis,